Dr. Liu graduated from the University of Toronto medicine program, followed by residencies at the University of Toronto and a fellowship at the Dana Farber Harvard Cancer Center in Boston. He was Assistant Professor of Medicine at Harvard Medical School before returning in 2006 to the Ontario Cancer Institute–Princess Margaret Cancer Centre. Trained in clinical and molecular epidemiology, he is the principal investigator of over three dozen completed, ongoing and upcoming cancer pharmacogenomic and molecular epidemiologic analyses of cancer observational studies and clinical trials funded by the National Cancer Institute (US), Canadian Cancer Trials Group, Canadian Cancer Society Research Institute, the Canadian Institute of Health Research, the Ontario Institute of Cancer Research, Cancer Care Ontario, Terry Fox Research Institute, Doris Duke Foundation and the Lung Cancer Foundation of America. He has research interests in epidemiological outcomes database methods, novel analyses of high dimensionality biologically rich data, pharmacogenomic analyses of conventional and molecularly targeted agents using primary human xenograft models, patient-reported outcomes in pharmacogenomics, and knowledge translation of personalized medicine and pharmacogenomic algorithms into clinical practice.